Aktarım Tamamlandı — 

Dermatologic Adverse Events Related to the PI3Kα Inhibitor Alpelisib (BYL719) in Patients with Breast Cancer

PURPOSE: Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of alpelisib-related dermatologic adverse events (dAEs). METHODS: A single center ret...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res Treat
Asıl Yazarlar: Wang, Diana G., Barrios, Dulce M., Blinder, Victoria S., Bromberg, Jacqueline F., Drullinsky, Pamela R., Funt, Samuel A., Jhaveri, Komal L., Lake, Diana E., Lyons, Tomas, Modi, Shanu, Razavi, Pedram, Sidel, Michelle, Traina, Tiffany A., Vahdat, Linda T., Lacouture, Mario E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398571/
https://ncbi.nlm.nih.gov/pubmed/32613539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05726-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller